Cenix BioScience has named Zisi Fotev as its new chief business officer.
Fotev joins Cenix from Atugen, where he served as vice president of business development. Prior to this, Cenix said, he served as head of licensing and strategic alliances at the pharmaceuticals division of Germany’s Merck.
Fotev holds a BS from the University of Western Australia and a PhD from the University of Tuebingen.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
